Status:
COMPLETED
The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The investigators hypothesize that the impaired insulinotropic effect of the incretin hormone GIP may be due to inadequate sensitization and ATP induced closure of beta cell K-ATP channels. By closing...
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus diagnosed according to WHO criteria
- Diet and/or metformin treatment
- HbA1c \> 7,0% for metformin treated patients
- HbA1c \> 7,5% for diet treated patients
- Age: 18 years or older
- 25 \> BMI \> 40 kg/m2
- Signed informed consent
- Sufficient birth control in case of child bearing capacity
Exclusion
- Proliferative retinopathy
- Diabetic nephropathy with s-creatinine \> 130 microM and/or macroalbuminuria
- Liver disease (ALAT \> 2 x normal value)
- CAD (NYHA group III or IV)
- Positive screening for islet-cell and/or GAD-65 autoantibodies
- Type 1 diabetes i first degree relatives
- Gastrointestinal surgery with intestinal resection
- Anemia
- Pregnancy and/or breastfeeding
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00321321
Start Date
May 1 2006
End Date
April 1 2007
Last Update
July 16 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Internal Medicine, Gentofte University Hospital
Hellerup, Copenhagen, Denmark, 2900